Home
Porcine Circovirus
Virus Alert
History
Prevalence
Clinical Signs
Diagnosis
Cost of Disease
Vaccination
Overall Management
Technical Information
Suvaxyn PCV2 One Dose
Label Information
Unique Formulation
Features and Benefits
Safety
Efficacy
Literature
FAQ
The Minds Behind
Links
 
FORT DODGE
 
Wyeth Animal Health
 
 
Efficacy
 

Proven Effective in Preventing Viremia and Reducing Lymphoid Depletion

Study Design

  • 44 healthy, 4-week-old, mixed-breed commercial pigs
  • Housed communally (vaccinates and controls commingled for the duration of the study)
  • Pigs were selected based on serological results for PCV2 antibody titer
  • Selected pigs were randomized into vaccine and control groups as follows:



  • The study was blinded for observations, sampling, necropsies and lab sample evaluations
  • Nasal swabs were collected on Day 0 post-vaccination to ensure there was no PCV2 infection in test animals prior to vaccination
  • During the post-vaccination observation period, 1 control pig was removed from the study for reasons not related to vaccination (swollen joints)
  • Pigs were vaccinated on Day 0 and challenged 6 weeks later (42 days)
Results
  • Daily rectal temperatures were measured from Day - 2 to Day 21/22 post-challenge
  • No significant differences in body temperature and no clinical signs were noted, except for one control pig at 15 days post-challenge
  • Compared to control group pigs, the vaccinated group had:
    • A significantly lower percentage of viremic pigs
    • A significantly lower percentage of pigs with moderate to severe lymphoid depletion
    • A significantly lower percentage of pigs with moderate to severe histiocytic replacement
    • A significantly lower percentage of pigs with medium to high levels of immunohistochemistry staining









 
Home  |  Contact Us  |  Sitemap  |  Privacy  |  Terms & Conditions

© 2007 Fort Dodge Animal Health, a division of Wyeth. This site is intended for residents of the United States and Canada.